Want to see TSE:ENBI.X full AI Analyst Report?
Entheon Biomedical (ENBI.X) Ratios
Entheon Biomedical Ratios
TSE:ENBI.X's free cash flow for Q4 2025 was $-60.38K. For the 2025 fiscal year, TSE:ENBI.X's free cash flow was increased by $0.00 and operating cash flow was $-60.38K. See a summary of the company’s cash flow.
| Ratios | Feb 26 | Feb 25 | Feb 24 | Feb 23 | Feb 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 11.72 | 10.41 | 4.64 | 4.81 | 3.46 |
| Quick Ratio | 11.72 | 10.41 | 4.64 | 4.81 | 3.43 |
| Cash Ratio | 10.82 | 7.88 | 4.04 | 4.40 | 2.21 |
| Solvency Ratio | -10.89 | 0.37 | 0.16 | -55.09 | -9.58 |
| Operating Cash Flow Ratio | -10.58 | -20.54 | -4.22 | -12.64 | -6.05 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 319.03K | $ 140.33K | $ 310.75K | $ 589.57K | $ 2.28M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.27 | 1.27 | 1.25 | 1.10 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.96 | 0.43 | -24.63 | 0.19 | 0.25 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 100.00% | 100.00% | 42.13% |
| EBIT Margin | 0.00% | 0.00% | -119.85% | -1897.96% | -37909.55% |
| EBITDA Margin | 0.00% | 0.00% | 5.59% | -1896.91% | -37891.09% |
| Operating Profit Margin | 0.00% | 0.00% | -125.04% | -1897.96% | -37891.09% |
| Pretax Profit Margin | 0.00% | 0.00% | -119.85% | -1086.58% | -36912.78% |
| Net Profit Margin | 0.00% | 0.00% | -119.85% | -4492.37% | -41010.61% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -119.85% | -1086.58% | -36912.78% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 413.44% | 111.10% |
| EBT Per EBIT | 96.94% | 95.50% | 95.85% | 57.25% | 97.42% |
| Return on Assets (ROA) | -91.58% | -171.76% | -74.80% | -1107.74% | -89.07% |
| Return on Equity (ROE) | -99.99% | -218.82% | -95.01% | -1386.49% | -98.20% |
| Return on Capital Employed (ROCE) | -103.15% | -198.42% | -99.13% | -585.77% | -90.73% |
| Return on Invested Capital (ROIC) | -103.15% | -198.42% | -99.13% | -585.77% | -90.73% |
| Return on Tangible Assets | -91.58% | -171.76% | -74.80% | -1107.74% | -218.04% |
| Earnings Yield | -26.85% | -29.35% | -50.77% | -48.07% | -2.90% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 40.15 | 4.50 | 0.77 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 |
| Asset Turnover | 0.00 | 0.00 | 0.62 | 0.25 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.56 | 0.13 | 0.01 |
| Cash Conversion Cycle | 0.00 | 0.00 | 9.09 | -24223.10 | -25763.89 |
| Days of Sales Outstanding | 0.00 | 0.00 | 9.09 | 81.19 | 476.67 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 762.25 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 24304.30 | 27002.81 |
| Operating Cycle | 0.00 | 0.00 | 9.09 | 81.19 | 1238.92 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.05 | -0.06 | -0.03 | -0.10 |
| Free Cash Flow Per Share | -0.02 | -0.05 | -0.06 | -0.03 | -0.10 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -57.32 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -57.32 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -1.44 | -10.30 | -259.12 |
| Free Cash Flow Yield | -26.08% | -32.82% | -60.91% | -11.03% | -1.86% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.72 | -3.41 | -1.97 | -2.08 | -34.53 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 2.36 | 93.45 | 14162.37 |
| Price-to-Book (P/B) Ratio | 3.72 | 7.46 | 1.87 | 28.84 | 33.91 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.83 | -3.05 | -1.64 | -9.07 | -53.72 |
| Price-to-Operating Cash Flow Ratio | -3.83 | -3.05 | -1.64 | -9.07 | -54.65 |
| Price-to-Earnings Growth (PEG) Ratio | 0.09 | 0.18 | 0.03 | 0.17 | 0.38 |
| Enterprise Value Multiple | -2.65 | -2.98 | 17.60 | -4.74 | -37.13 |
| Enterprise Value | 884.78K | 946.97K | 246.27K | 17.05M | 304.85M |
| EV to EBITDA | -2.65 | -2.98 | 17.60 | -4.74 | -37.13 |
| EV to Sales | 0.00 | 0.00 | 0.98 | 89.87 | 14067.81 |
| EV to Free Cash Flow | -2.81 | -2.66 | -0.68 | -8.72 | -53.36 |
| EV to Operating Cash Flow | -2.81 | -2.66 | -0.68 | -8.72 | -54.29 |
| Tangible Book Value Per Share | 0.02 | 0.02 | 0.05 | 0.01 | 0.06 |
| Shareholders’ Equity Per Share | 0.02 | 0.02 | 0.05 | 0.01 | 0.16 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 |
| Net Income Per Share | -0.02 | -0.04 | -0.05 | -0.14 | -0.16 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 4.13 | 1.11 |
| Interest Burden | 0.97 | 1.00 | 1.00 | 0.57 | 0.97 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 6.32 | 55.93 |
| SG&A to Revenue | 0.00 | 0.00 | 2.25 | 13.33 | 221.42 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.45 | 117.79 |
| Income Quality | 0.97 | 1.12 | 1.20 | 0.95 | 0.63 |
Currency in CAD
